#### 1 SMARCA4 Mutations in KRAS-mutant Lung Adenocarcinoma: A Multi-cohort 2 Analysis

3

Liang Liu<sup>1,2#</sup>\*, Tamjeed Ahmed<sup>3#</sup>, W. Jeffrey Petty<sup>2,3</sup>, Stefan Grant<sup>1,3</sup>, Jimmy Ruiz<sup>3</sup>, Thomas W. Lycan<sup>3</sup>, Umit Topaloglu<sup>1,2</sup>, Ping-Chieh Chou<sup>1,2</sup>, Lance D. Miller<sup>1,2</sup>, Gregory A. 4 5 Hawkins<sup>1,4</sup>, Martha A. Alexander-Miller<sup>5</sup>, Stacey S. O'Neill<sup>1,6</sup>, Bayard L. Powell<sup>3</sup>, Ralph B. D'Agostino, Jr.<sup>1,7</sup>, Reginald F. Munden<sup>8</sup>, Boris Pasche<sup>1,2,3</sup>, Wei Zhang<sup>1,2,7</sup>\* 6 7

8 <sup>1</sup>Center for Cancer Genomics and Precision Oncology, Wake Forest Baptist

Comprehensive Cancer Center, Departments of <sup>2</sup>Cancer Biology, <sup>3</sup>Internal Medicine-9

- Section of Hematology and Oncology, <sup>4</sup>Biochemistry, <sup>5</sup>Microbiology and Immunology, <sup>6</sup>Pathology and Laboratory Medicine, <sup>7</sup>Biostatistical Sciences, and <sup>8</sup>Radiology, Wake 10
- 11
- Forest School of Medicine, Winston-Salem, NC, USA 27157 12
- 13
- <sup>#</sup>Contributed equally 14
- 15
- 16
- 17
- 18 **Corresponding Authors**
- Wei Zhang, Tel: +1 336 713 7508; E-mail: wezhang@wakehealth.edu 19
- 20 Liang Liu, Tel: +1 336 713 7514; E-mail: lliu@wakehealth.edu
- Department of Cancer Biology, Wake Forest Baptist Comprehensive Cancer Center, 21

Wake Forest Baptist Medical Center, Medical Center Blvd., Winston-Salem, NC, 27157, 22

USA. 23

### 1 ABSTRACT

2 **Background** *KRAS* is a key oncogenic driver in lung adenocarcinoma (LUAD).

Chromatin-remodeling gene *SMARCA4* was co-mutated with *KRAS* in LUAD; however,
the impact of *SMARCA4* mutations on clinical outcome has not been adequately
established. This study sought to shed light on the clinical significance of *SMARCA4*

6 mutations in LUAD.

7 Methods The association of SMARCA4 mutations with survival outcomes was

8 interrogated in 4 independent cohorts totaling 564 patients: KRAS-mutant patients with

9 LUAD who received non-immunotherapy treatment from 1) The Cancer Genome Atlas

10 (TCGA) and 2) the MSK-IMPACT Clinical Sequencing (MSK-CT) cohorts; and KRAS-

11 mutant patients with LUAD who received immune checkpoint inhibitor-based

immunotherapy treatment from 3) the MSK-IMPACT (MSK-IO) and 4) the Wake Forest

13 Baptist Comprehensive Cancer Center (WFBCCC) immunotherapy cohorts.

14 **Results** Of the patients receiving non-immunotherapy treatment, in the TCGA cohort

15 (n=155), KRAS-mutant patients harboring SMARCA4 mutations (KS) showed poorer

16 clinical outcome (*P*=6e-04 for disease-free survival (DFS) and .031 for overall survival

17 (OS), respectively), compared to KRAS-TP53 co-mutant (KP) and KRAS-only mutant (K)

18 patients; in the MSK-CT cohort (n=314), KS patients also exhibited shorter OS than KP

19 (P=.03) or K (P=.022) patients. Of patients receiving immunotherapy, KS patients

20 consistently exhibited the shortest progression-free survival (PFS; P=.0091) in the MSK-

IO (n=77), and the shortest PFS (P=.0026) and OS (P=0.0014) in the WFBCCC (n=18)

22 cohorts, respectively.

- 1 Conclusions mutations of SMARCA4 represent a genetic factor that lead to adverse
- 2 clinical outcome in lung adenocarcinoma treated by either non-immunotherapy or
- 3 immunotherapy.

### 1 BACKGROUNDS

2 Lung cancer is the leading cause of cancer-related death worldwide, with 5-year 3 survival rates of ~18%. Non-small cell lung cancer (NSCLC) comprises 85% of all lung 4 cancer cases, mainly including adenocarcinoma (LUAD), squamous cell carcinoma 5 (LUSC), and large cell carcinoma. Great strides have been made in recent years with 6 the development of immune checkpoint inhibitor treatment targeting PD-1/PD-L1 7 mediated immunosuppression, which have shown efficacy in up to 30% of NSCLC 8 patients [1-6]. Expression of PD-1/PD-L1 was reported to be associated with enhanced 9 benefits from immunotherapy, but debates exist because of discordant results across 10 different studies [1, 2, 4-11]. Currently, a higher tumor mutation burden (TMB) is 11 undergoing evaluation as a predictive biomarker in many tumor types [7, 12-14]. The mutations in KRAS are a common oncogenic driver in ~20% NSCLC [15, 16]. The 12 goal of developing specific therapeutic strategies for the KRAS-mutant patients has thus 13 14 far proven elusive. For example, KRAS mutations are associated with shortest survivals 15 in NSCLC patients treated with carboplatin plus paclitaxel as well as single anti-EGFR TKI agent [17]. Recently, it was shown that STK11/LKB1 or TP53 co-mutations can 16 17 stratify KRAS-mutant LUAD patient into different subgroups with distinct biology, therapeutic vulnerabilities and immune profiles [18], and immunotherapy response [19]. 18 The SWItch/Sucrose NonFermentable (SWI/SNF) complex is a major chromatin 19 20 remodeling complex that controls DNA accessibility to transcriptional factors and 21 regulates transcriptional programming [20]. Genomic alterations in the components of 22 the SWI/SNF chromatin remodeling complex have been identified in multiple types of 23 cancers [21]. A recent study reported that mutations in the chromatin remodeling gene

1	PBRM1 were associated with response to immunotherapy through IFN- $\gamma$ signaling
2	pathway, a key effector for antitumor T cell function, in clear cell renal cell carcinoma
3	[22, 23]. Mutations in the PBRM1 in NSCLC is rare; however, mutations in the
4	SMARCA4 gene occur frequently in NSCLC [16, 24] and tended to co-occur with KRAS
5	mutations [16]. One recent study showed that SMARCA4 acted as a tumor suppressor
6	by cooperating with p53 loss and Kras activation, and SMARCA4-mutant tumors were
7	sensitive to inhibition of oxidative phosphorylation [25]. Another study showed that the
8	reduced expression of SMARCA4 contributes to poor outcomes in lung cancer [26].
9	However, the prognostic values of SMARCA4 mutations in KRAS-mutant LUAD patients
10	who received either non-immunotherapy or immunotherapy treatment have not been
11	well defined.
12	In this study, we evaluated the prognostic value of SMARCA4 mutations in KRAS-
13	mutant LUAD within four independent cohorts consisting of patients received non-
14	immunotherapy or immunotherapy treatment.
15	
16	
17	METHODS
18	For the Cancer Genome Atlas (TCGA) cohort, matched somatic mutation, gene
19	expression and clinical data of 560 patients with LUAD were retrieved. We obtained the

- 20 clinical and somatic mutation data of 62 principal tumor types for MSK-IMPACT Clinical
- 21 Sequencing Cohort and extracted the data of LUAD patients [27]. We excluded patients
- 22 who received immunotherapy treatment indicated in their later publication [14] (as the

MSK-IO cohort including 186 patients) to establish an MSK-CT cohort of 1033 patients
 received non-immunotherapy treatment.

3	We extracted the 127 LUAD patients who were treated with immunotherapy between
4	March 1, 2015 and November 30, 2017 at the Wake Forest Baptist Comprehensive
5	Cancer Center (WFBCCC) immune-oncology program. Efficacy was assessed by the
6	treating physician and categorized according to RECIST guidelines [28] and defined as
7	durable clinical benefit (DCB; complete response [CR]/partial response [PR] or stable
8	disease [SD] that lasted > 6 months) or no durable benefit (NDB, PD or SD that lasted $\leq$
9	6 months). Progression-free survival (PFS) was defined as the time from the date of
10	initial immunotherapy administration to the date of progression or death, and overall
11	survival (OS) was to the date of death or last follow-up, respectively. If the patient was
12	alive at the date of last contact, his/her data were censored at that time point. Genomic
13	profiles were available for 39 patients who were enrolled into the Wake Forest Precision
14	Oncology Initiative (ClinicalTrials.gov Identifier: NCT02566421).
15	Only patients harboring KRAS mutations and with survival data were included in the
16	study, resulting in 155 (27.7% of 560) and 314 (30.4% of 1033) patients received non-
17	immunotherapy treatment in the TCGA and MSK-CT cohorts, and 77 (41.4% of 186)
18	and 18 (46.2% of 39) patients received immunotherapy treatment in the MSK-IO and

19 the WFBCCC cohorts.

# 20 Statistical Analysis

Tests used to analyze clinical and genomic data included the Mann-Whitney U test (two-group comparisons),  $\chi^2$  test (three-group comparisons), Fisher's exact test (proportion comparisons). Survival curves were estimated using Kaplan-Meier
methodology and compared between two groups using the log-rank test and Cox
proportional hazards regression analysis. Hazard ratios (HRs) and 95% CIs were
generated by Cox proportional hazards models where *P*<.05 and these statistics were</li>
estimable (i.e., when at least one event occurred in both groups being compared). All
analyses were performed using R software, version 3.2.1.

- 8
- 9 **RESULTS**

# 10 SMARCA4 Mutations are Associated with Shorter Survival of Patients Who

# 11 Received Non-immunotherapy Treatment

12 KRAS is one of the most frequently mutated genes in LUAD, which occur in 155 (30%) 13 patients in the TCGA cohort. These patients were reprehensive of the overall LUAD 14 cohort with median patient age of 67 years (range 33-87) and high percentage of 15 current/former smokers (94.8%). 5.8% (9) of the KRAS-mutant patients harbored 16 SMARCA4 mutations in the TCGA cohort and were classified as KS; 33.5% (52) 17 patients harbored TP53 mutations and were classified as the KP subgroup; and 60.6% (94) patients did not carry SMARCA4 or TP53 mutations and were classified as K 18 19 (Supplementary Figure 1). The SMARCA4 mutations were not associated with any 20 risk factors such as age at diagnosis, tumor stage, race/ethnicity or smoking history 21 (Supplementary Table 1).

1 Disease-free survival (DFS) differed between the three groups (P=6e-4), with 2 significantly shorter DFS for patients in the KS subgroup compared to either KP (HR 3 4.47, 95% CI 1.52-13.22, P=.003) or K (HR 2.43 95% CI 1.46-4.05, P=1.2e-4) patients 4 in pair-wise comparisons (Figure 1A). In contrast, KP and K patient had similar DFS (P=.64). We also compared the survivals between KS (SMARCA4-mutant) and KP+K 5 6 (SMARCA4-wildtype) patients, and found that KS patients exhibited significantly shorter DFS (HR 5.34 95% CI 2.05-14.14, *P*=1.3e-4) (**Figure 1B**). 7 8 Overall survival (OS) also varied significantly between the three groups (P=.031). The 9 KS patients exhibited shorter DFS than the K subgroup (HR 1.63, 95% CI 1.05-2.55, 10 P=.024). Although the difference of OS between KS and KP was not significant (P=.21), the median OS in KS was 15.37 months compared to 18.48 months in KP (Figure 1C). 11 12 In addition, the two-group comparison showed significantly shorter OS in KP (SMARCA4-mutant) compared to K+KP (SMARCA4-wildtype) patients (HR 2.32, 95%) 13 CI 1.01-5.44, *P*=.047) (Figure 1D). 14 We validated these observations in an independent MSK-CT cohort [27], consisting of 15 314 KRAS-mutant patients. High percentage of current/former smokers (78.0%) were 16 17 also observed. Across the entire cohort, 10.8% (34) patients were classified as KS, 34.1% (107) were KP and 55.1% (173) were K (Supplementary Figure 1 and Table 2). 18 Significantly shorter OS were observed for patients with KS compared to K (HR 1.39, 95% 19 20 CI 1.04-1.85, *P*=.022) or KP (HR 1.94, 95% CI 1.06-3.57, *P*=.03) (Figure 2A), and K 21 and KP have similar OS (*P*=.99). In the two-group comparison, OS was significantly 22 shorter in KS (SMARCA4-mutant) compared to K+KP (SMARCA4-wildtype) patients 23 (HR 1.95, 95% CI 1.13-3.38, *P*=.015) (**Figure 2B**).

#### **1** SMARCA4 Mutations are Associated with Shorter Survival of Patients Who

#### 2 **Received Immunotherapy Treatment**

3 We then examined whether SMARCA4 mutations impacted KRAS-mutant patient 4 response to immunotherapy. 77 LUAD patients harboring KRAS mutations were 5 extracted from the MSK-IO cohort [14]. The median age of patients was 68 (range 37-6 86) and the majority (93.5%) was ever smokers. Based on SMARCA4 and TP53 mutation status, 11.7% (9) tumors were classified as KS, 32.5% (25) were KR, and 55.8% 7 (43) were K. Demographic and clinical characteristics were generally well balanced 8 9 between the co-mutation defined groups. The clinical benefit rates to immunotherapy in KS, KP and K groups was not significantly different (P=.42), probably due to the small 10 11 sample size; however, smaller proportion of KS patients (2/9=22.2%) achieved durable 12 clinical benefit (DCB) than KP (10/23=43.5%) or K (13/43=30.2%) patients.

### 13 (Supplementary Figure 1 and Table 3).

14 Significantly different PFS was observed between the three groups (P=.0091). The KS 15 patients exhibited the shorter PFS compared to KP (HR 2.82, 95% CI 1.17-6.81, P=.016) tumors in pair-wise comparisons. Although the difference of PFS between KS and K 16 17 was not significant (P=.18), the median OS in KS was 1.73 months compared to 2.77 months in KP. Interestingly, KP patients exhibited longer survival than K patients (HR 18 0.48, 95% CI 0.26-0.86, *P*=.012) (**Figure 3A**). We merged the KP and K patients to test 19 20 the difference between SMARCA4-mutant and wildtype patients. SMARCA4-mutant (KS) patients exhibit significantly shorter PFS than wildtype (K+KP) patients (HR 2.15, 95%) 21 CI 1.46-4.35, *P*=.048, median PFS 1.73 vs. 4.22 months) (Figure 3B). 22

1 We also validated the prognostic values of SMARCA4 mutations in KRAS-mutant LUAD 2 patients upon immunotherapy using 18 patient samples from the WFBCCC. Patients were classified into KS (11.1%), KR (44.4%) and K (44.4%) subgroups 3 (Supplementary Figure 1 and Table 4). In this small cohort, the clinical benefit rates to 4 5 checkpoint inhibitor-based immunotherapy in KS, KP and K groups were significantly 6 different (*P*=.03). KS patients were resistant to treatment, while KP patients were mostly sensitive. 7 8 The three groups of *KRAS*-mutant LUAD patients exhibited significantly different OS 9 (P=.042) and PFS (P=.0014). The KS patients exhibited the shortest OS and PFS 10 compared to either KR (HR 2.46, 95% CI 1.05-6.61, P=.0019 and P=.0019 with HR and 11 95% CI evaluable) and K (HR 2.46, 95% CI 1.01-6.61, P=.042 and HR 3.06, 95% CI 12 1.03-10.28, *P*=.029) patients in pair-wise comparisons (**Figures 4A and 4C**). Further significantly deceased OS and PFS was observed in KS (SMARCA4-mutant) patients 13 compared to K+KP (wildtype) ones (HR 11.98, 95% CI 1.66-26.6, P=.0018 and HR 18.7, 14 15 95% CI 1.65-21.6, P=.0011) (Figures 4B and 4D), consistent with the observations in 16 the MSK-IO cohort. Altogether, these data indicated that SMARCA4 abrogation likely

17 determines immunotherapy resistance in *KRAS*-mutant LUAD.

# 18 SMARCA4 Mutations are Significantly Enriched among Tumors with

# 19 Immunosuppressive Tumor Microenvironment

20 We interrogated the composition of immune cells in the tumor microenvironment of

21 patients from the TCGA cohort which has RNA-seq data available. Using CIBERSOFT

- 22 [29] to quantify the proportion of each individual immune cell type, we found that KS
- 23 patients had significantly lower estimated proportions of CD8 and activated CD4

memory T cells than either K (*P*=.015 and .035) or KS (*P*=.043 and .023), while no
differences between KP and K patients (*P*=.66 and .35), indicating an
immunosuppressive tumor microenvironment in the KS patients (Figure 5 and
Supplementary Figure 2).

### 5 **DISCUSSION**

6 Alterations in chromatin remodeling complex, SWI/SNF, including SMARCA4, have been found in NSCLC [16, 24, 30, 31]. In this study, we interrogated the clinical 7 significance of SMARCA4 mutations in KRAS-mutant LUAD in the TCGA and the MSK-8 9 CT cohorts in the absence of immunotherapy and the MSK-IO and the WFBCCC 10 cohorts who received immunotherapy. Our analysis indicates that genomic alterations in 11 the chromatin remodeling gene, SMARCA4, as a negative prognostic factor to KRAS-12 mutant LUAD patients no matter received non-immunotherapy or immunotherapy treatment. The mutations may induce an immunosuppressive tumor environment by 13 14 modulating the immune cell components. Although the completed determinants of 15 response to treatment is not yet completed defined, our study suggests that nonimmunotherapy and immune checkpoint inhibitor-based immunotherapy treatment may 16 17 not benefit this subset of patients.

18 More frequent *KRAS* mutations were observed in ever smokers than that occurred in

never smokers [24, 32-34], and associated with a significant increase of TMB [35].

20 Previous studies indicated that a subset of KRAS-mutant NSCLC patients may have a

- 21 better response to immunotherapy treatment [2, 35, 36]. We determined that KP
- 22 patients exhibited better survival than KS and K patients when receiving immune
- 23 checkpoint inhibitor-based immunotherapy, which is consistent with previous report [35].

1	The underlying mechanism may be that KP patients contained the largest proportion of
2	CD8 and activated CD4 memory T cells, supporting by previous report that TP53 and
3	KRAS mutations had remarkable effects on increasing PD-L1 expression, facilitating T-
4	cell infiltration and augmenting tumor immunogenicity [35].
5	SMARCA4 inactivation was shown to promotes NSCLC aggressiveness by altering
6	chromatin organization [30], and the reduced expression of SMARCA4 contributes to
7	poor outcomes in lung cancer [26]. Here we showed that SMARCA4-KRAS co-mutant
8	patients (KS) exhibited poorer survival of patients who received either non-
9	immunotherapy or immunotherapy treatment. On the other hand, quantitative IHC for
10	BRG1 can capture SMARCA4-deficient tumor [37, 38] which is associated with
11	SMARCA4 mutations (Supplementary Figure 3). Therefore, evaluation of BRG1
12	expression by IHC may further enhance the predictive utility for non-immunotherapy or
13	immunotherapy treatment to NSCLC.
14	SMARCA4 mutation is a unique biomarker for the stratification of KRAS-mutant patients
15	with LUAD. SMARCA4 mutations are not associated with other factors such as
16	STK11/LKB1 mutations, which can stratify KRAS-mutant LUAD into different subgroups
17	with distinct biology, therapeutic vulnerabilities and immune profiles [18] and
18	immunotherapy response [19], because mutations in SMARCA4 and STK11/LKB1 did
19	not co-occur in KRAS-mutant patients receiving immunotherapy treatment in the MSK-
20	IO (P=0.065) or WFBCCC (P=0.41) cohorts. In addition, STK11 mutations did not serve
21	as a prognostic marker for patients who received non-immunotherapy treatment [19, 39-
22	41].

1 For these patients harboring both KRAS and SMARCA4 mutations, an alternative 2 treatment strategy is required. A clinical study showed that cisplatin-based 3 chemotherapy benefited NSCLC patients with low SMARCA4 expression [26]. Another 4 report indicated the activity of AURKA, which encodes a cell-cycle regulated kinase, 5 was essential in NSCLC cells lacking SMARCA4, and the inhibition/depletion of AURKA 6 enabled apoptosis and cell death *in vitro* and in xenograft mouse models [42]. Moreover, a recent study indicated that SMARCA4-deficient lung cells and xenograft tumors 7 8 displayed marked sensitivity to inhibition of oxidative phosphorylation [25]. All 9 observations suggested encouraging treatment strategies but need further testing in

10 clinics.

# 11 CONCLUSIONS

- 12 We provide evidence that *SMARCA4* mutations are associated with poor clinical
- 13 survival outcomes of KRAS-mutant LUAD patients. If confirmed in additional cohorts, it
- 14 is likely that future prediction models will need to include *SMARCA4* mutations.

# 15 **ABBREVIATIONS**

- 16 **LUAD**: Lung adenocarcinoma
- 17 **KS**: KRAS-SMARCA4 co-mutant
- 18 **KP**: KRAS-TP53 co-mutant
- 19 K: KRAS-only mutant
- 20 LUSC: Lung squamous carcinoma
- 21 NSCLC: Non-small cell lung cancer

- 1 **TCGA**: The Cancer Genome Atlas (TCGA)
- 2 MSK-CT: the MSK-IMPACT Clinical Sequencing cohort
- 3 MSK-IO: MSK-IMPACT cohort
- 4 **WFBCCC**: the Wake Forest Baptist Comprehensive Cancer Center
- 5 **DCB**: durable clinical benefit

### 1 Acknowledgement

- 2 W.Z. is supported by the Hanes and Willis Professorship in Cancer and a Fellowship
- 3 from the National Foundation for Cancer Research. B.P. is supported by the Charles L.
- 4 Spurr Professorship Fund. We thank Dr. Matthew S. Hellman at the MSKCC for helpful
- 5 discussion of the results especially in regard to the MSK-IO cohort. We also
- 6 acknowledge the editorial assistance of Karen Klein, MA, in the Wake Forest Clinical
- 7 and Translational Science Institute, and Dr. Mac Robinson at the WFBCCC.

# 8 Funding

- 9 The work is supported by the Cancer Center Support Grant to the Comprehensive
- 10 Cancer Center of Wake Forest Baptist Medical Center (P30CA012197).

### 11 Availability of data and materials

- 12 All relevant data and materials within this work are made available in this manuscript or
- 13 previously published.

### 14 Authors' contributions

15 All authors have participated in drafting, reading, and approving the final manuscript.

# 16 **Competing interests**

17 The authors declare that they have no competing interests.

# 18 **Consent for publication**

- 19 Not applicable.
- 20 Ethics approval and consent to participate

1 Approval for the FoundationOne test were obtained from the ethics committee.

# 1 References

2 Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, 1. 3 Gubens M. Horn L et al: Pembrolizumab for the treatment of non-small-cell lung 4 cancer. N Engl J Med 2015, 372(21):2018-2028. 5 2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip 6 E. Holgado E et al: Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-7 Cell Lung Cancer. N Engl J Med 2015, 373(17):1627-1639. 8 Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, 3. 9 Pluzanski A, Vokes EE, Holgado E et al: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015, 373(2):123-135. 10 Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, 11 4. 12 Smith D, Artal-Cortes A, Lewanski C et al: Atezolizumab versus docetaxel for patients 13 with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, 14 phase 2 randomised controlled trial. Lancet 2016, 387(10030):1837-1846. 15 5. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, 16 Ahn MJ et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. 17 18 Lancet 2016, 387(10027):1540-1550. 19 6. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, 20 Tafreshi A, Cuffe S et al: Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-21 Small-Cell Lung Cancer. N Engl J Med 2016, 375(19):1823-1833. 22 7. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel 23 MM, Ciuleanu TE, Badin F et al: First-Line Nivolumab in Stage IV or Recurrent Non-24 Small-Cell Lung Cancer. N Engl J Med 2017, 376(25):2415-2426. 25 8. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida 26 T, Kowalski DM, Dols MC et al: Atezolizumab versus docetaxel in patients with 27 previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, 28 multicentre randomised controlled trial. Lancet 2017, 389(10066):255-265. 29 Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, 9. 30 Spasic M, Henry G, Ciobanu V et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515(7528):568-571. 31 32 Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott 10. 33 DF, Powderly JD, Gettinger SN et al: Predictive correlates of response to the anti-PD-L1 34 antibody MPDL3280A in cancer patients. Nature 2014, 515(7528):563-567. 35 11. Liu L, Ruiz J, O'Neill SS, Grant SC, Petty WJ, Yang M, Chen K, Topaloglu U, Pasche B, 36 Zhang W: Favorable outcome of patients with lung adenocarcinoma harboring POLE 37 mutations and expressing high PD-L1. Mol Cancer 2018, 17(1):81. 38 Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong 12. P, Ho TS et al: Cancer immunology. Mutational landscape determines sensitivity to PD-39 1 blockade in non-small cell lung cancer. Science 2015, 348(6230):124-128. 40

Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, 1 13. 2 Foppen MHG, Goldinger SM et al: Genomic correlates of response to CTLA-4 blockade 3 in metastatic melanoma. Science 2015, 350(6257):207-211. 4 14. Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, 5 Sauter JL, Rekhtman N et al: Molecular Determinants of Response to Anti-Programmed 6 Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients 7 With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. 8 Journal of clinical oncology : official journal of the American Society of Clinical Oncology 9 2018, 36(7):633-641. 10 Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, 15. Capelletti M. Sivachenko A et al: Mapping the hallmarks of lung adenocarcinoma with 11 12 massively parallel sequencing. Cell 2012, 150(6):1107-1120. 13 16. Cancer Genome Atlas Research N: Comprehensive molecular profiling of lung 14 adenocarcinoma. Nature 2014, 511(7511):543-550. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne 15 17. 16 PA, Januario T, Johnson DH et al: Mutations in the epidermal growth factor receptor 17 and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin 18 19 Oncol 2005, 23(25):5900-5909. 20 18. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara 21 H, Parra ER, Canales JR et al: Co-occurring genomic alterations define major subsets of 22 KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and 23 therapeutic vulnerabilities. Cancer Discov 2015, 5(8):860-877. 24 Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock 19. 25 AB, Hartmaier RJ, Trabucco SE, Gay L et al: STK11/LKB1 Mutations and PD-1 Inhibitor 26 Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 2018. 27 Becker PB, Workman JL: Nucleosome remodeling and epigenetics. Cold Spring Harb 20. 28 Perspect Biol 2013, 5(9). 29 21. Helming KC, Wang X, Roberts CWM: Vulnerabilities of mutant SWI/SNF complexes in 30 cancer. Cancer cell 2014, 26(3):309-317. 31 22. Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, 32 Lim K, Rao P et al: A major chromatin regulator determines resistance of tumor cells to 33 T cell-mediated killing. Science 2018, 359(6377):770-775. 34 Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bosse D, Wankowicz 23. 35 SM, Cullen D et al: Genomic correlates of response to immune checkpoint therapies in 36 clear cell renal cell carcinoma. Science 2018, 359(6377):801-806. 37 24. Cancer Genome Atlas Research N: Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489(7417):519-525. 38 39 Deribe YL, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, 25. 40 Khor T, Feng N et al: Mutations in the SWI/SNF complex induce a targetable 41 dependence on oxidative phosphorylation in lung cancer. *Nature Medicine* 2018:1. 42 Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, Stegmaier P, McNulty M, 26. 43 Karachaliou N, Rosell R et al: SMARCA4/BRG1 Is a Novel Prognostic Biomarker

1 2		Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer. Clin Cancer Res 2016, 22(10):2396-2404.
3 4	27.	Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM <i>et al</i> : <b>Mutational landscape of metastatic cancer revealed from</b>
5 6 7	28.	prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> 2017, 23(6):703. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M <i>et al</i> : New response evaluation criteria in solid tumours:
8 9		revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England : 1990) 2009, 45(2):228-247.
10	29.	Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh
11 12		methods 2015, <b>12</b> (5):453-457.
13 14 15	30.	Orvis T, Hepperla A, Walter V, Song S, Simon J, Parker J, Wilkerson MD, Desai N, Major MB, Hayes DN <i>et al</i> : <b>BRG1/SMARCA4 inactivation promotes non-small cell lung cancer</b>
15 16		6498.
17	31.	Huang HT, Chen SM, Pan LB, Yao J, Ma HT: Loss of function of SWI/SNF chromatin
18 10		remodeling genes leads to genome instability of human lung cancer. Oncology reports
20	32	Lee W liang 7 Liu I Haverty PM Guan Y Stinson I Yue P Zhang Y Pant KP Bhatt D <i>et</i>
21	521	<i>al</i> : The mutation spectrum revealed by paired genome sequences from a lung cancer
22		patient. <i>Nature</i> 2010, <b>465</b> (7297):473-477.
23	33.	Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R,
24		Fulton L, Wallis J et al: Genomic landscape of non-small cell lung cancer in smokers and
25	24	never-smokers. Cell 2012, 150(6):1121-1134. Design GD. Denissenke ME. Olivier M. Tretvekeve N. Hecht SS. Heineut D. Tehecce
20 27	54.	smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
28		Oncogene 2002. <b>21</b> (48):7435-7451.
29	35.	Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q <i>et al</i> :
30		Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1
31		Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res 2017, 23(12):3012-
3Z 22	26	3024. Ock CV, Keen R, Kim S, Lee JS, Kim M, Kim TM, Jeen VK, Kim DW, Chung DH, Hee DS.
22 21	50.	Ban Cancer Immunegenemic Perspective on the Tumor Microenvironment Pased on
24 25		PD-11 and CD8 T-Cell Infiltration Clin Cancer Res 2016 <b>27</b> (9):2261-2270
36	37.	Karanian-Philippe M. Velasco V. Longy M. Floquet A. Arnould L. Coindre IM. Le Naoures-
37	571	Mear C. Averous G. Guvon F. MacGrogan G et al: SMARCA4 (BRG1) loss of expression is
38		a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic
39		type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic
40		tumors, 9 soft tissue tumors, and 9 melanomas. Am J Surg Pathol 2015, 39(9):1197-
41		1205.
42	38.	Clarke BA, Witkowski L, Ton Nu TN, Shaw PA, Gilks CB, Huntsman D, Karnezis AN, Sebire
43		N, Lamovec J, Roth LM et al: Loss of SMARCA4 (BRG1) protein expression as
44		determined by immunohistochemistry in small-cell carcinoma of the ovary,

1		hypercalcaemic type distinguishes these tumours from their mimics. <i>Histopathology</i>
2		2016, <b>69</b> (5):727-738.
3	39.	Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit
4		DB, Hellmann M et al: Effects of Co-occurring Genomic Alterations on Outcomes in
5		Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 2018,
6		<b>24</b> (2):334-340.
7	40.	Bonanno L, De Paoli A, Zulato E, Esposito G, Calabrese F, Favaretto A, Santo A, Conte AD,
8		Chilosi M, Oniga F et al: LKB1 Expression Correlates with Increased Survival in Patients
9		with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and
10		Bevacizumab. Clin Cancer Res 2017, <b>23</b> (13):3316-3324.
11	41.	Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remon
12		J, Soria JC, Lacroix L, Besse B: LKB1/STK11 mutations in non-small cell lung cancer
13		patients: Descriptive analysis and prognostic value. Lung Cancer 2017, 112:62-68.
14	42.	Tagal V, Wei S, Zhang W, Brekken RA, Posner BA, Peyton M, Girard L, Hwang T, Wheeler
15		DA, Minna JD et al: SMARCA4-inactivating mutations increase sensitivity to Aurora
16		kinase A inhibitor VX-680 in non-small cell lung cancers. <i>Nat Commun</i> 2017, 8:14098.
17		

### 1 FIGURE LEGENDS

2 **Figure 1**: *SMARCA4* mutations are associated with shorter disease-free survival (DFS)

3 and overall survival (OS) of KRAS-mutant LUAD patients treated with non-

4 immunotherapy treatment from the TCGA cohort. Kaplan-Meier survival analysis of

5 survival in (AC) the KS, KP and K subgroups and (BD) in the two-group comparison

6 between SMRACA4-mutant and wildtype KRAS-mutant patients.

7 Figure 2: SMARCA4 mutations are associated with shorter overall survival (OS) of

8 KRAS-mutant LUAD patients treated with non-immunotherapy treatment from the MSK-

9 CT cohort. Kaplan-Meier survival analysis of OS (A) in the KS, KP and K subgroups and

10 (B) in the two-group comparison between SMRACA4-mutant and wildtype KRAS-

11 mutant patients.

12 **Figure 3**: *SMARCA4* mutations are associated with shorter progression-free survival

13 (PFS) of *KRAS*-mutant LUAD patients treated with immunotherapy treatment from the

14 MSK-IO cohort. Kaplan-Meier survival analysis of PFS (A) in the KS, KP and K

subgroups and (B) in the two-group comparison between SMRACA4-mutant and

16 wildtype *KRAS*-mutant patients.

Figure 4: *SMARCA4* mutations are associated with shorter progression-free survival
(PFS) and overall survival (OS) of *KRAS*-mutant LUAD patients treated with
immunotherapy treatment from the WFBCCC cohort. Kaplan-Meier survival analysis of
survival (AC) in the KS, KP and K subgroups and (BD) in the two-group comparison
between *SMRACA4*-mutant and wildtype *KRAS*-mutant patients.

- 1 Figure 5: Tumor microenvironment varied among three groups of patients. KS patients
- 2 contained the lowest proportions of CD8 and activated CD4 memory T cells than either
- 3 K or KP patients. The plot for all 22 types of immune cells was shown in
- 4 **Supplementary Figure 2**. \**P*<.05; Mann-Whitney U test.
- 5

# 1 SUPPLEMENTAL CONTENT

- 2 **Supplementary Table 1:** *KRAS*-mutant patient Characteristics in the TCGA cohort
- 3 treated with non-immunotherapy.
- 4 Supplementary Table 2: KRAS-mutant patient Characteristics in the MSKCC-CT
- 5 cohort treated with non-immunotherapy.
- 6 **Supplementary Table 3:** *KRAS*-mutant patient Characteristics in the MSK-IO cohort
- 7 treated with immunotherapy.
- 8 Supplementary Table 4: KRAS-mutant patient Characteristics in the WFBCC cohort
- 9 treated with immunotherapy.

- 11 Supplementary Figure 1: Global somatic mutation landscape of *KRAS*, *TP53* and
- 12 SMARCA4 genes in the TCGA, MSK-CT, MSK-IO and WFBCCC cohorts.
- 13 Supplementary Figure 2: The comparisons of estimated proportions of immune cell
- 14 subsets, as calculated by CIBERSORT among K, KP and KS patients. Across all cell
- types, the proportions of CD8 T cells and activated CD4 memory T cells differ
- significantly in the comparisons of K vs. KS and KP vs. KS (shown in Figure 5).
- 17 **Supplementary Figure 3:** *SMARCA4* mutations are associated with lower expression
- 18 level of SMARCA4.









